S

surgezirc.co.za

@surgezirc Tue, 24 Feb 2026 10:03:04

Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China

UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk In a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeks UBT251 appeared The post Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China appeared first on SurgeZirc SA | Breaking News, SA News, World News, Videos.

read more

Other Headlines